3.14
+0.08(+2.61%)
Currency In USD
| Previous Close | 3.06 |
| Open | 3.1 |
| Day High | 3.15 |
| Day Low | 3.03 |
| 52-Week High | 4.87 |
| 52-Week Low | 2.12 |
| Volume | 5.79M |
| Average Volume | 9.17M |
| Market Cap | 1.61B |
| PE | -39.25 |
| EPS | -0.08 |
| Moving Average 50 Days | 2.81 |
| Moving Average 200 Days | 3.38 |
| Change | 0.08 |
If you invested $1000 in Clover Health Investments, Corp. (CLOV) since IPO date, it would be worth $307.84 as of September 16, 2025 at a share price of $3.14. Whereas If you bought $1000 worth of Clover Health Investments, Corp. (CLOV) shares 3 years ago, it would be worth $1,408.07 as of September 16, 2025 at a share price of $3.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Counterpart Health Launches Integrated Scribing, Supercharging Counterpart Assistant with Smarter, Seamless Scribing Built for Value-Based Care
GlobeNewswire Inc.
Sep 09, 2025 12:30 PM GMT
The latest AI-powered feature in Counterpart Assistant streamlines documentation, enhances physician workflows, and raises the bar for value-based care across practice settings at no additional cost to usersSAN FRANCISCO, Sept. 09, 2025 (GLOBE NEWS
Clover Health CEO Andrew Toy Testifies Before Congress on the Transformative Role of AI in Healthcare, Highlights how Clover is Leading the Way
GlobeNewswire Inc.
Sep 03, 2025 6:20 PM GMT
WASHINGTON, D.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) – Clover Health CEO Andrew Toy today had the honor to deliver testimony before the U.S. House of Repre
Primary Care Physician Use of Counterpart Assistant Technology Linked to Better Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease
GlobeNewswire Inc.
Aug 04, 2025 8:30 PM GMT
New whitepaper shows that a relationship with a primary care physician (“PCP”) who uses Counterpart Assistant is correlated with more frequent Chronic Obstructive Pulmonary Disease (“COPD”) diagnosis, increased specialty care, and meaningful reductio